Content area
Full Text
http://crossmark.crossref.org/dialog/?doi=10.1007/s11064-016-1922-0&domain=pdf
Web End = Neurochem Res (2016) 41:20972101 DOI 10.1007/s11064-016-1922-0
http://crossmark.crossref.org/dialog/?doi=10.1007/s11064-016-1922-0&domain=pdf
Web End = ORIGINAL PAPER
b-Asarone Inhibits IRE1/XBP1 Endoplasmic Reticulum Stress Pathway in 6-OHDA-Induced Parkinsonian Rats
Baile Ning1 Minzhen Deng1 Qinxin Zhang1 Nanbu Wang1 Yongqi Fang2
Received: 14 February 2016 / Revised: 8 April 2016 / Accepted: 13 April 2016 / Published online: 21 April 2016 Springer Science+Business Media New York 2016
Abstract Parkinsons disease (PD) is a neurodegenerative disease, with genetics and environment contributing to the disease onset. The limited pathological cognize of the disease restrained the approaches to improve the clinical treatment. Recently, studies showed that endoplasmic reticulum (ER) stress played an important role in the pathogenesis of PD. There was a neuroprotective effect partly mediated by modulating ER stress. b-Asarone is the essential constituent of Acorus tatarinowii Schott volatile oil. Our team observed that b-asarone could improve the behavior of parkinsonian rats; increase the HVA, Dopacl, and 5-HIAA levels; and reduce a-synuclein levels. Here we assumed that the protective role of b-asarone on parkinsonian rats was mediated via ER stress pathway. To prove the hypothesis we investigated the mRNA levels of glucose regulated protein 78 (GRP78) and C/EBP homologous binding protein (CHOP) in 6-hydroxy dopamine (6-OHDA) induced parkinsonian rats after b-asarone treatment. Furthermore, the inositol-requiring enzyme 1/XBox Binding Protein 1 (IRE1/XBP1) ER stress pathway was also studied. The results showed that b-asarone inhibited the mRNA levels of GRP78 and CHOP, accompanied with the delined expressions of phosphorylated IER1 (p-IRE1) and XBP1. We deduced that b-asarone
might have a protective effect on the 6-OHDA induced parkinsonian rats via IRE1/XBP1 Pathway. Collectively, all data indicated that b-asarone might be a potential candidate of medicine for clinical therapy of PD.
Keywords b-Asarone Parkinsons disease IRE1
XBP1 Endoplasmic reticulum stress
Introduction
Parkinsons disease (PD) is the second most common neurodegenerative disorder of aging and the most common movement disorder [1]. The pathological features showed that dopaminergic neurons lost in the substantia nigra pars compacta (SNpc) [2]. Lewy bodies had been considered to be a marker for neuronal degeneration, because neuronal loss was found in the predilection sites for Lewy bodies [3]. Studies observed that a-synuclein was one of the major components of Lewy bodies, abnormal a-synuclein deposition occurred early in PD [4]. In addition, oxidative...